Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2020 / Cilt: 28 - Sayı: 1

Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment

Küçük hücreli dışı akciğer kanserinde neoadjuvan tedavi sonrası patolojik tam yanıtın prognostik önemi

Pages
166–174
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Survival of patients with a pathological completeresponse is also significantly longer than unresponsive patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to investigate the factors associated withpathological complete response following neoadjuvant treatment andto examine the prognostic value of pathological complete response inpatients with non-small cell lung cancer undergoing surgical resection.Methods: Between February 2009 and January 2016, a total of 112patients (96 males, 16 females; mean age 60±8 years; range, 37 to 85years) with the diagnosis of non-small cell lung cancer who underwentanatomical pulmonary resection after neoadjuvant treatment wereretrospectively analyzed.
📊
Key Findings & Data:Predictive factors for pathological completeresponse and its prognostic significance were analyzed.Results: The mean follow-up was 35±20 (range, 0 to 110) months.Of the patients, 30 (27%) achieved a pathological complete response.Reduction rate in tumor size was significantly higher in theresponsive group (32.5±21.6% vs. 19.2±18.8%, respectively) andwas a predictor of pathological complete response independentfrom the T and N factors (p=0.004).
💡
Conclusion & Impact:Survival of patients with a pathological completeresponse is also significantly longer than unresponsive patients.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to investigate the factors associated withpathological complete response following neoadjuvant treatment andto examine the prognostic value of pathological complete response inpatients with non-small cell lung cancer undergoing surgical resection.Methods: Between February 2009 and January 2016, a total of 112patients (96 males, 16 females; mean age 60±8 years; range, 37 to 85years) with the diagnosis of non-small cell lung cancer who underwentanatomical pulmonary resection after neoadjuvant treatment wereretrospectively analyzed. Demographic, clinical, radiological, andpathological characteristics of the patients were recorded. Thepatients were classified as pathological complete response and nonpathologicalcomplete response according to the presence of tumorsin the pathology reports. Predictive factors for pathological completeresponse and its prognostic significance were analyzed.Results: The mean follow-up was 35±20 (range, 0 to 110) months.Of the patients, 30 (27%) achieved a pathological complete response.Reduction rate in tumor size was significantly higher in theresponsive group (32.5±21.6% vs. 19.2±18.8%, respectively) andwas a predictor of pathological complete response independentfrom the T and N factors (p=0.004). Survival of the responsivepatients was significantly longer than unresponsive patients(75±9 vs. 30±4 months, respectively; p<0.001). During follow-up,tumor recurrence was seen in 30 patients. Recurrence was observedin only one patient in the responsive group, while 29 patients in theunresponsive group had recurrence or metastasis.Conclusion: Tumor shrinkage rate after neoadjuvant treatment innon-small cell lung cancer is a predictive factor for pathologicalcomplete response. Survival of patients with a pathological completeresponse is also significantly longer than unresponsive patients.

Özet

Amaç: Bu çalışmada cerrahi rezeksiyon yapılan küçük hücreli dışı akciğer kanserli hastalarda neoadjuvan tedavi sonrası patolojik tam yanıt ile ilişkili faktörler araştırıldı ve patolojik tam yanıtın prognostik değeri incelendi. Çalışma planı: Şubat 2009 - Ocak 2016 tarihleri arasında küçük hücreli dışı akciğer kanseri tanısı konulan ve neoadjuvan tedavi sonrasında anatomik pulmoner rezeksiyon yapılan toplam 112 hasta (96 erkek, 16 kadın; ort. yaş 60±8 yıl; dağılım, 37-85 yıl) retrospektif olarak incelendi. Hastaların demografik, klinik, radyolojik ve patolojik özellikleri kaydedildi. Hastalar patoloji raporunda tümör varlığına göre patolojik tam yanıt ve patolojik tam yanıt olmayanlar olmak üzere sınıflandırıldı. Patolojik tam yanıtın öngördürücü faktörleri ve prognostik önemi incelendi. Bulgular: Ortalama takip süresi 35±20 (dağılım, 0-110) ay idi. Hastaların 30’unda (%27) patolojik tam yanıt elde edildi. Tümör boyutunda görülen küçülme oranı, yanıt veren grupta anlamlı düzeyde daha yüksek olup (sırasıyla %19.2±18.8’e kıyasla %32.5±21.6), T ve N faktörlerinden bağımsız olarak, patolojik tam yanıtın bir öngördürücü idi (p=0.004). Yanıt veren hastaların sağkalım süresi, yanıt vermeyenlere kıyasla anlamlı düzeyde daha uzundu (sırasıyla, 30±4 aya kıyasla 75±9 ay, p<0.001). Takip süresince 30 hastada tümör nüksü izlendi. Yanıt veren grupta bir hastada nüks gözlenir iken, yanıt vermeyen grupta 29 hastada nüks veya metastaz izlendi. Sonuç: Küçük hücreli dışı akciğer kanserinde neoadjuvan tedavi sonrası tümör küçülme oranı, patolojik tam yanıtın öngördürücü bir faktörüdür. Ayrıca patolojik tam yanıtlı hastaların sağkalım süresi, yanıt vermeyen hastalara kıyasla anlamlı düzeyde daha uzundur.

🔖

Cite This Article

GÜRER, D., AKYIL, F. T., AKYIL, M., TEZEL, Ç., EVMAN, S., ALPAY, L., BAYSUNGUR, V., YALÇINKAYA, İ. (2022). Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 28 - Sayı: 1, 166–174. https://ajindex.com/articles/423690

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. World Health Organization. International Agency for Research on Cancer (IARC) GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 3. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019;11:943-53. 4. Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, et al. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site. J Thorac Oncol 2013;8:860-5. 5. Lewis J, Gillaspie EA, Osmundson EC, Horn L. Before or After: Evolving neoadjuvant approaches to locally advanced non-small cell lung cancer. Front Oncol 2018;8:5. 6. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. 7. Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg 2012;93:1807-12. 8. Bharat AGB, Rusch VW, Bains MS, Rizk NP. Role of PET scan in predicting response to neoadjuvant chemotherapy and long-term outcome for stage II cancer. ASCO Meet Abstr 2014;32(15 suppl):7574. 9. Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 2018;13:1818-31. 10. Coroller TP, Agrawal V, Narayan V, Hou Y, Grossmann P, Lee SW, et al. Radiomic phenotype features predict pathological response in non-small cell lung cancer. Radiother Oncol 2016;119:480-6. 11. Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol 2012;7:841-9. 12. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-smallcell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-106. 13. Katakami